

# CITATION REPORT

List of articles citing

**Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants**

**DOI: 10.1111/jth.14457**

**Journal of Thrombosis and Haemostasis, 2019, 17, 1064-1072.**

**Source:** <https://exaly.com/paper-pdf/73258019/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
66	Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants. <i>Journal of Thrombosis and Haemostasis</i> , <b>2019</b> , 17, 1064-1072	15.4	43
65	Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2020</b> , 49, 294-303	5.1	14
64	The relationship between DOAC levels and clinical outcomes: The measures tell the tale. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 3163-3168	15.4	6
63	Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e017316	6	5
62	Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system. <i>Thrombosis Research</i> , <b>2020</b> , 196, 276-282	8.2	8
61	Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure. <i>Blood Advances</i> , <b>2020</b> , 4, 3520-3527	7.8	6
60	Concomitant Administration of Direct Oral Anticoagulants in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors. <i>Clinical Drug Investigation</i> , <b>2020</b> , 40, 1177-1187	3.2	2
59	Off-label use of reduced dose direct oral factor Xa inhibitors in subjects with atrial fibrillation: a review of clinical evidence. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2021</b> , 7, 334-345	6.4	5
58	Drug-Drug Interactions between Direct Oral Anticoagulants and Hepatitis C Direct-Acting Antiviral Agents: Looking for Evidence Through a Systematic Review. <i>Clinical Drug Investigation</i> , <b>2020</b> , 40, 1001-1008	3.2	3
57	Potential Drug Interactions between Recombinant Interleukin-2 and Direct Oral Anticoagulants: Indirect Evidence from In Vivo Animal Studies. <i>Hamostaseologie</i> , <b>2020</b> , 40, 679-686	1.9	0
56	Letter by Kallmøzer et al Regarding Article, "Safety of Intravenous Thrombolysis Among Patients Taking Direct Oral Anticoagulants: a Systematic Review and Meta-Analysis". <i>Stroke</i> , <b>2020</b> , 51, e130-e131	6.7	6
55	Anti-Factor Xa Activity of Standard and Japan-Specific Doses of Rivaroxaban in Thai Patients With Non-Valvular Atrial Fibrillation. <i>Circulation Journal</i> , <b>2020</b> , 84, 1075-1082	2.9	0
54	Should we monitor the direct oral anticoagulants?. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2020</b> , 50, 30-32	5.1	4
53	Direct oral anticoagulant plasma levelsStriking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 1320-1323	15.4	103
52	The management of patients with acute ischemic stroke while on direct oral anticoagulants (DOACs): data from an Italian cohort and a proposed algorithm. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2020</b> , 50, 732-738	5.1	5
51	Position paper on the safety/efficacy profile of Direct Oral Anticoagulants in patients with Chronic Kidney Disease: Consensus document of Societ�Italiana di Nefrologia (SIN), Federazione Centri per la diagnosi della trombosi e la Sorveglianza delle terapie Antitrombotiche (FCSA) and Societ�Italiana per lo Studio dell'Emostasi e della Trombosi (SISET). <i>Journal of Nephrology</i> , <b>2021</b> , 34, 31-38	4.8	3
50	Critical Analysis of Apixaban Dose Adjustment Criteria. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2021</b> , 27, 10760296211021158	3.3	1

49	2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. <i>Thrombosis and Haemostasis</i> , <b>2021</b> , 121, 1008-1020 <sup>7</sup> <sup>21</sup>		
48	The use of direct acting oral anticoagulants in patients with COVID-19 infection. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , <b>2021</b> , 11, 184-186	1.1	2
47	The relationship between DOAC levels and clinical outcomes: The measures tell the tale-Response from original authors Lijfering et al. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 1136-1138	15.4	0
46	Evaluation of Anti-Xa Apixaban and Rivaroxaban Levels With Respect to Known Doses in Relation to Major Bleeding Events. <i>Journal of Pharmacy Practice</i> , <b>2021</b> , 8971900211009075	1.3	2
45	Direct oral anticoagulant blood level monitoring in daily practice. <i>Thrombosis Update</i> , <b>2021</b> , 3, 100049	0.9	1
44	Spinal Cord Compression Secondary to a Spontaneous Spinal Haematoma in a Patient Newly Treated with Rivaroxaban. <i>European Journal of Case Reports in Internal Medicine</i> , <b>2021</b> , 8, 002593	1.2	0
43	Does atorvastatin therapy change the anti-Xa activity in xabans-treated patients with atrial fibrillation?. <i>Pharmacology Research and Perspectives</i> , <b>2021</b> , 9, e00730	3.1	1
42	Influence of age on the relationship between apixaban concentration and anti-factor Xa activity in older patients with non-valvular atrial fibrillation. <i>International Journal of Cardiology</i> , <b>2021</b> , 331, 109-113 <sup>3,2</sup>		1
41	Impact of Weight on Clinical Outcomes of Edoxaban Therapy in Atrial Fibrillation Patients Included in the ETNA-AF-Europe Registry. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	1
40	ROTEM Testing for Direct Oral Anticoagulants. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2021</b> , 47, 815-823 <sup>3</sup>	3.3	2
39	Causes of an elevated international normalized ratio in the intensive care unit and the implications for plasma transfusion. <i>Transfusion</i> , <b>2021</b> , 61, 2862-2868	2.9	1
38	Direct Oral Anticoagulants Plasma Levels in Patients with Atrial Fibrillation at the Time of Bleeding: A Pilot Prospective Study. <i>Journal of Cardiovascular Pharmacology</i> , <b>2021</b> , 78, e122-e127	3.1	3
37	Use of Direct Oral Anticoagulants in Patients With Antiphospholipid Syndrome: A Systematic Review and Comparison of the International Guidelines. <i>Frontiers in Cardiovascular Medicine</i> , <b>2021</b> , 8, 715878	5.4	5
36	Current therapeutic approaches to haemostasis correction in covid-19: a systematic review. <i>Kuban Scientific Medical Bulletin</i> , <b>2021</b> , 28, 72-84	0.2	
35	A comprehensive review of DOACs for cancer associated VTE prophylaxis or treatment. <i>Postgraduate Medicine</i> , <b>2021</b> , 133, 71-79	3.7	2
34	Automated Thrombin Generation Assay for Rivaroxaban, Apixaban, and Edoxaban Measurements. <i>Frontiers in Cardiovascular Medicine</i> , <b>2021</b> , 8, 717939	5.4	0
33	Different Coagulation Indicators in Predicting Clinical Outcomes for Patients With Direct Oral Anticoagulants: A Systematic Review and Meta-analysis. <i>Clinical Therapeutics</i> , <b>2020</b> , 42, 2066-2081.e9	3.5	2
32	Dabigatran plasma concentration indicated the risk of patients with non-valvular atrial fibrillation. <i>Heart and Vessels</i> , <b>2021</b> , 1	2.1	0

31	Assessment of exposure to direct oral anticoagulants in elderly hospitalised patients. <i>British Journal of Haematology</i> , <b>2021</b> , 195, 790-801	4.5	0
30	Anti-Xa Activity-Guided Edoxaban Therapy for Cancer-Associated Venous Thromboembolism?. <i>American Journal of Therapeutics</i> , <b>2020</b> ,	1	0
29	Inter- and intra-individual concentrations of direct oral anticoagulants: The KIDOAC study. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 20, 92	15.4	3
28	Position paper on the safety/efficacy profile of direct oral anticoagulants in patients with chronic kidney disease. Consensus document from the SIN, FCSA and Siset. <i>Blood Transfusion</i> , <b>2020</b> , 18, 478-485 <sup>3,6</sup>		
27	Dodging blood brain barrier with "nano" warriors: Novel strategy against ischemic stroke.. <i>Theranostics</i> , <b>2022</b> , 12, 689-719	12.1	3
26	Monitoring of Direct Oral Anticoagulants Plasma Levels for Secondary Stroke Prevention.. <i>Journal of Thrombosis and Haemostasis</i> , <b>2022</b> ,	15.4	1
25	A Combined Pharmacometrics Analysis of Biomarker Distribution Under Treatment With Standard- or Low-Dose Rivaroxaban in Real-World Chinese Patients With Nonvalvular Atrial Fibrillation.. <i>Frontiers in Pharmacology</i> , <b>2022</b> , 13, 814724	5.6	1
24	Simvastatin, but Not Atorvastatin, Is Associated with Higher Peak Rivaroxaban Serum Levels and Bleeding: an Asian Cohort Study from Singapore.. <i>Cardiovascular Drugs and Therapy</i> , <b>2022</b> ,	3.9	1
23	Apixaban Monitoring: The Jury Is Still Out. <b>2022</b> , 1, 100038		
22	Plasma Rivaroxaban Level in Patients With Early Stages of Chronic Kidney Disease Relationships With Renal Function and Clinical Events. <i>Frontiers in Pharmacology</i> , <b>2022</b> , 13,	5.6	0
21	Apixaban Concentrations in Routine Clinical Care of Older Adults With Nonvalvular Atrial Fibrillation. <b>2022</b> , 1, 100039		1
20	A systematic review and meta-analysis of dabigatran peak and trough concentration in adults. <i>British Journal of Clinical Pharmacology</i> ,	3.8	
19	Do Apixaban Plasma Levels Relate to Bleeding? The Clinical Outcomes and Predictive Factors for Bleeding in Patients with Non-Valvular Atrial Fibrillation. <b>2022</b> , 10, 2001		0
18	Population Pharmacokinetics and Dose Optimization Based on Renal Function of Rivaroxaban in Thai Patients with Non-Valvular Atrial Fibrillation. <b>2022</b> , 14, 1744		2
17	Twice- or once-daily dosing of direct oral anticoagulants and gastrointestinal bleeding in patient with atrial fibrillation. <b>2022</b> , 22, 100203		0
16	Approach to Thromboprophylaxis for Prevention of Venous Thromboembolism in COVID-19: Global Updates and Clinical Insights from India. <b>2022</b> , 12, 766-781		0
15	The Myths Behind DOAC Measurement: Analyses of Prescribing Information from Different Regulatory Bodies and a Call for Harmonization.		0
14	Implementation of the new EUR IVD regulation and relation with ISO15189 accreditation: Guidance is urgently required for haemostasis testing. <b>2022</b> , 44, 71-78		1

13	Direct oral to parenteral anticoagulant transitions: Role of factor Xa inhibitor-specific anti- X a concentrations.	0
12	Coagulation Assays and Direct Oral Anticoagulant Levels Among Patients Having an Elective Surgery or Procedure.	0
11	The non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with high-normal renal function <b>IA</b> systematic review. <b>2022</b> , 107123	0
10	Tailored Direct Oral Anticoagulation in Patients with Atrial Fibrillation: The Future of Oral Anticoagulation?. <b>2022</b> , 11, 6369	0
9	TAVR: nemesis of NOACs?.	0
8	Safety and efficacy of direct oral anticoagulants in geriatric patients with non-valvular atrial fibrillation: A single-center retrospective study. <b>2022</b> ,	0
7	Eight pharmacokinetic genetic variants are not associated with the risk of bleeding from direct oral anticoagulants in non-valvular atrial fibrillation patients. 13,	1
6	Plasma apixaban levels in Chinese patients with chronic kidney diseaseRelationship with renal function and bleeding complications. 13,	0
5	Circulating miR-320a-3p and miR-483-5p level associated with pharmacokineticpharmacodynamic profiles of rivaroxaban. <b>2022</b> , 16,	0
4	Safety and Efficacy Re-Evaluation of Edoxaban and Rivaroxaban Dosing With Plasma Concentration Monitoring in Non-Valvular Atrial Fibrillation: With Observations of On-Label and Off-Label Dosing. <b>2023</b> , 5, 80-89	0
3	The role of anticoagulation clinics needs to be reassessed to include follow up of patients on direct oral anticoagulants. <b>2023</b> , 225, 11-15	0
2	DOACs plasma levels in relation to clinical outcome. How far have we come?. <b>2023</b> , 225, 16-21	0
1	Clinical characteristics of patients with direct oral anticoagulant (DOAC) levels outside expected ranges: A retrospective chart study. <b>2023</b> , 100139	0